# Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model

> **NCT04072302** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 86 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** KAF156
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04072302
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-15
- **Primary completion:** 2017-11-29
- **Final completion:** 2017-11-29
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04072302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04072302, "Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04072302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*